In September, the director of the DEA resigned. Chuck Rosenberg had been the acting head of the agency but had yet to fully take over the agency. While replacements circle the position, what’s important to understand is what this means for CBD moving forward. A lot has changed, as much as it hasn’t.
Where CBD stands with the DEA
The DEA’s handling of CBD rights in America has left a lot to be desired. Following the passage of the 2014 Farm Bill, the DEA fought the definition of what constitutes hemp well into the winter of 2017. While industrial hemp is allowed to cultivate in government-sponsored programs, such as the one Ananda Hemp participates in, the DEA confounds this by wavering in and out of police actions.
So, what is next for CBD advocacy? CBD advocates should keep a strong eye towards the future of the Industrial Hemp Farming Act. If the DEA has to abide by Hemp being completely removed from Schedule I classification, then relations will likely improve. Until then, it’s a roll of the dice in terms of how the next DEA director will approach CBD products.
This information is presented for educational purposes only. Ananda Hemp developed this information to provide an understanding of the potential applications of cannabinoids. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.